Cytokinetics (CYTK) Expected to Post Earnings on Wednesday

Cytokinetics (NASDAQ:CYTK) is expected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Cytokinetics to post earnings of ($1.44) per share and revenue of $41.20 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. During the same quarter in the previous year, the firm posted ($1.12) earnings per share. Cytokinetics’s revenue for the quarter was down 57.1% on a year-over-year basis. On average, analysts expect Cytokinetics to post ($5.97) EPS for the current fiscal year and ($4.65) EPS for the next fiscal year.

Cytokinetics Trading Up 1.3%

CYTK stock opened at $61.52 on Wednesday. The firm has a 50 day moving average of $68.37 and a 200-day moving average of $70.08. Cytokinetics has a 12-month low of $58.05 and a 12-month high of $88.31.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CYTK. HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of Cytokinetics in a research report on Monday, October 19th. Citizens Jmp boosted their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research note on Tuesday, September 1st. William Blair started coverage on shares of Cytokinetics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.44.

Insiders Place Their Bets

In other Cytokinetics news, Director B. Parshall sold 5,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the transaction, the director owned 10,784 shares of the company’s stock, valued at $770,840.32. This represents a 31.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the sale, the executive vice president owned 58,555 shares in the company, valued at $4,677,373.40. This trade represents a 19.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 183,926 shares of company stock valued at $12,937,330. Insiders own 2.60% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.